BioMarker STRATEGIES

News Release

Scott Allocco, BioMarker Strategies
410-522-1008
sallocco@biomarkerstrategies.com
Elizabeth Bruckheimer, Champions Oncology
201-808-8400
EBruckheimer@championsoncology.com

FOR IMMEDIATE RELEASE
April 9, 2013

BioMarker Strategies and Champions Oncology Announce Results of Scientific Collaboration at AACR:
Functional Profiling of Champions' TumorGraft™ Melanoma Models using BioMarker Strategies' SnapPath™ Live Tumor Testing System

Washington, D.C.--April 9, 2013—BioMarker Strategies and Champions Oncology, Inc. (OTC: CSBR) announced the results of their scientific collaboration today at the Annual Meeting of the American Association of Cancer Research. In their joint poster session, the companies described their results generating Functional Signaling Profiles from Champions' human melanoma TumorGraft™ models, which were compared with in vivo efficacy, gene expression and genotype data.

"Our findings suggest that the combination of Champions' TumorGraft™ models with functional profiling of live tumor tissue with our SnapPath™ system may represent a powerful tool for pharmacodynamic assessment of targeted therapeutics in clinically relevant models. This has the potential to guide oncology drug development and, ultimately, choice of therapy." said Dr. Douglas Clark, CEO of BioMarker Strategies and senior author of the study.

"This collaboration demonstrates our continued efforts at enhancing the value of the Champions TumorGraft™ platform by providing additional ways to evaluate mechanism of action and biomarker signatures for oncology drug developers," said Elizabeth M. Bruckheimer, VP of Scientific Operations at Champions Oncology, and lead author of the study.

Molecularly targeted agents, such as the BRAF inhibitor vemurafenib, produce short-term responses in some patients; however, most patients are intrinsically resistant, or develop resistance through restructuring of signal transduction pathways which cannot be determined through traditional DNA analysis.

In their collaboration, the companies used the SnapPath™ live-cell-processing platform to produce Functional Signaling Profiles from fresh Champions TumorGraft™ tumor specimens, which had previously been collected from melanoma patients and implanted into immunodeficient mice. Fine needle aspiration biopsies were performed on each melanoma TumorGraft model and processed on the BioMarker Strategies' SnapPath™ platform to modulate tumor cell signal

transduction networks through brief ex vivo exposure to the vemurafenib tool compound PLX-4720. Cell lysates were then analyzed using a multiplexed immunoassay to assess the inhibition of the downstream MAPK markers pMEK1 and pERK-1/2.

Functional Signaling Profiles, comparing modulated levels of each phosphoprotein, were then created for each TumorGraft™ model. The in vivo sensitivity to vemurafenib and BRAF mutation status was evaluated in each Champions' TumorGraft™ model in parallel. Functional Signaling Profiles were then compared with in vivo efficacy, gene expression and genotype data. At the AACR Poster Session, the companies reported that Functional Signaling Profiles stratified the TumorGraft™ models into two distinct groups upon ex vivo exposure to a BRAF inhibitor: 1) MAPK markers suppressed and 2) MAPK markers not suppressed.

About BioMarker Strategies

BioMarker Strategies has developed its novel SnapPath™ live tumor cell processing system to generate Functional Signaling Profiles (FSPs) of solid tumors to promote improved cancer drug development and better inform selection of targeted therapies for cancer patients. Functional Signaling Profiles are phosphoprotein-based, phenotypic profiles derived from ex vivo exposure of fresh tumor samples to targeted therapies in the SnapPath™ device. These profiles provide information about the activated signal transduction network of live tumor cells that are not possible using static, traditional biomarkers from dead, fixed tumor tissue. The Company recently published data from its preclinical and clinical collaboration in advanced melanoma in PlosOne. While the Company's initial work has focused on advanced melanoma model systems and patients, comprehensive FSP profiles can be generated from other solid tumors, including colon, lung and breast cancers. The company is located at the Johns Hopkins Science + Technology Park in Baltimore. The development of the SnapPath™ system was supported with significant funding from the National Cancer Institute. For more information about BioMarker Strategies, please refer to www.biomarkerstrategies.com.

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's TumorGraft™ Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts™, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts™ are procured through agreements with a number of institutions in the U.S. and overseas as well as through its Personalized Oncology Solutions business.

# # # #

Forward Looking Statement

This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology and BioMarker Strategies generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. Both Companies' actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2012 for a discussion of such risks, uncertainties and other factors. Although both Companies believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and both companies' future results, levels of activity, performance or achievements may not meet these expectations. The Companies does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the companies' expectations, except as required by law.